PolyCore Therapeutics’ experienced team of scientists and life sciences professionals is dedicated to developing breakthrough treatments for CNS Diseases.
Nia Therapeutics, Inc. is focused on developing neurostimulation therapies aimed at treating memory impairment, particularly in patients who have suffered traumatic brain injuries. Founded in 2016 and based in Philadelphia, Pennsylvania, the company emerged from research at the University of Pennsylvania and was influenced by the United States BRAIN Initiative. Nia Therapeutics specializes in creating devices that analyze complex brain activity linked to memory function, delivering personalized therapy through deep-brain stimulation. This innovative approach seeks to enhance memory by restoring the brain activity essential for effective memory recall.
ChromaTan Inc. specializes in developing continuous countercurrent tangential chromatography (CCTC) technology for the purification of monoclonal antibodies and proteins. Founded in 2007 and located in Lower Gwynedd, Pennsylvania, the company addresses significant process bottlenecks in the production of therapeutic proteins by offering a cost-effective, column-free, and single-use purification solution. ChromaTan's CCTC platform has undergone extensive beta testing with numerous major biotech firms, demonstrating a 5 to 15 times increase in throughput while maintaining or improving product quality. This innovative technology provides a scalable alternative to traditional large-scale column chromatography processes, benefiting biotechnology and contract manufacturing companies by lowering production costs and enhancing efficiency.
Bainbridge Health, Inc. is a Philadelphia-based company that develops a clinical intelligence and data analytics platform focused on improving medication safety in hospital systems. Founded in 2016, the company provides solutions specifically for medication safety leaders, including an infusion pump management software known as InfusionWare. This platform allows clinicians to manage infusion data centrally, enhancing patient safety by streamlining data handling and reducing the likelihood of medication errors. Bainbridge Health’s vendor-agnostic approach eliminates the need for cumbersome data management practices, enabling hospitals to mitigate risks associated with medication errors while also lowering avoidable costs.
Cassian Solutions, Inc. is a company that develops and manufactures an innovative phone case medication dispenser, along with a comprehensive application designed to enhance patient compliance with medication regimens. Founded in 2018 and based in Phoenixville, Pennsylvania, the company focuses on improving patient monitoring and data reporting within the pharmaceutical value chain. Its offerings include features such as biometric verification, medication reminders, adherence verification, and real-time communication. Cassian Solutions serves a range of clients, including pharmacies, clinical trial companies, drug manufacturers, and insurers, addressing critical gaps in patient care that can lead to poor health outcomes and increased healthcare costs. By integrating medication delivery with smartphone technology, Cassian Solutions aims to transform the medication-taking experience and facilitate better treatment adherence.
SFA Therapeutics, Inc. is a development-stage bio-pharmaceutical company located in Jenkintown, Pennsylvania. The company specializes in the discovery and manufacturing of microbiome-derived metabolites for use as therapeutic drugs. Its primary focus is on chronic inflammatory diseases, cancer, and autoimmune conditions. By leveraging compounds found in the human microbiome, SFA Therapeutics aims to provide innovative treatment options to medical professionals seeking to address these complex health issues.
AAPlasma is developing a cold plasma-based system that is based on previously-successful technology capable of achieving in-between-patient decontamination of PPE items to allow for rapid reuse.
Optical Inventory Solutions is the creators of ViewVax.ViewVax is the industry leader in automated vaccine inventory. ViewVax’s simple and seamless design fits into a preexisting medical refrigerator allowing hospitals, clinics, and doctors’ offices the opportunity to utilize and organize their current medical refrigerators while integrating the automated inventory solution hardware and software. ViewVax’s web-connected, camera counts on-hand vaccine inventory, allowing for automatic reordering, reduced inventory levels, and easy identification of vaccines.
Navrogen, Inc. is a biopharmaceutical company based in Philadelphia, Pennsylvania, established in 2017. The company focuses on the targeted treatment of cancer by developing technology platforms that enhance the immune system's ability to combat tumors. Navrogen's innovative approach involves identifying tumor-produced proteins that suppress the body's humoral immune response, which can hinder the effectiveness of cancer treatments. By assembling a database of tumor types that produce these immuno-suppressive factors, Navrogen aims to enable physicians to better understand and overcome the challenges posed by these proteins, ultimately improving therapeutic outcomes for patients with cancer.
MBF Therapeutics, Inc. is a clinical-stage veterinary oncology company dedicated to developing innovative therapies for dogs and cats with cancer. The company's portfolio includes targeted immunotherapies and small molecule drugs designed to disrupt tumor cell metabolism while sparing normal healthy cells. Notable products in development include MBFT-101, a combination therapy for sarcomas and lymphoma that merges a polyamine transport inhibitor with a potent enzyme inhibitor, and MBFT-102, an immunotherapy based on the tumor suppressor mda-7/IL24, which has shown promise in human cancers. Additionally, MBF Therapeutics is exploring gene-based immunotherapeutic vaccines, aiming to revolutionize cancer treatment and infectious disease prevention in companion animals and livestock. The company collaborates with the Lankenau Institute for Medical Research and is headquartered in Ambler, Pennsylvania.
BINTO LLC designs and manufactures fertility supplements, women's health supplements, and organic period products. It offers supplement pouch, slide out box for personalized day packs, and organic and chemical free tampons. The company was founded in 2015 and is headquartered in Philadelphia, Pennsylvania.
POLARIS HEALTH DIRECTIONS develops and markets behavioral health outcomes assessment and management systems to help deliver better health outcomes at a reduced cost. Polaris systems are designed for use by health care providers, managed care organizations, government agencies and pharmaceutical companies, and focus on addressing the impact mental health conditions have on physical health and an individual’s welfare. These solutions help Polaris's clients identify, monitor and address psychosocial and behavioral health conditions to curb long-term health effects and costs.
PolyCore Therapeutics’ experienced team of scientists and life sciences professionals is dedicated to developing breakthrough treatments for CNS Diseases.
Mitochon Pharmaceuticals, Inc. is a biotechnology company established in 2014 and based in Blue Bell, Pennsylvania. The company is dedicated to developing drugs that target mitochondrial function, aiming to address significant unmet medical needs in treating serious diseases. Its primary focus is on neurodegenerative and neuromuscular disorders, including Huntington's disease, Alzheimer's disease, Parkinson's disease, Duchenne muscular dystrophy, and epilepsy, among others. Mitochon is also exploring potential therapies for metabolic disorders related to over-nutrition, such as diabetes and obesity. The company's research is grounded in the understanding that various diseases are linked to mitochondrial dysfunction, and by correcting these malfunctions, Mitochon seeks to pave the way for innovative disease-modifying therapies. The leadership team comprises experienced industry professionals with a strong commitment to advancing breakthrough drug therapies for conditions with limited treatment options.
Allevi develops tools for designing and engineering 3D tissues, specializing in desktop 3D bioprinters that create functional living tissues. The company's offerings include bioinks composed of collagen and hyaluronic acid, alongside a cloud-based platform called Bioprint Online, which allows users to design structures, define materials, and monitor the printing process. Allevi's products are utilized by researchers in tissue engineering, regenerative medicine, material science, and cell biology, as well as by industrial and pharmaceutical companies for drug testing and development. The company's bioinks are available for purchase online. Founded in 2014 and based in Philadelphia, Pennsylvania, Allevi was previously known as BioBots, Inc.
Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics.
Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.
Atrin Pharmaceuticals LLC is a biopharmaceutical company based in Doylestown, Pennsylvania, focused on the discovery and development of innovative cancer treatments. Founded in 2011, the company specializes in proprietary medications, including ATRN-502, a p53 activator, and ATRN-507, a dual ligand that selectively targets cancer cells. Atrin's advanced research is centered on developing a new class of compounds that act as specific inhibitors of ATR, a crucial mediator in DNA repair. The company utilizes its proprietary screening platform, Atrize, which enables high-throughput evaluation of drug candidates and personalized medicine approaches. This platform allows for the rapid identification of compounds that effectively inhibit cancer cell viability while minimizing effects on healthy cells, thus advancing the potential for more effective cancer therapies.
TowerView helps the 1 in 3 Americans with a chronic illness manage multiple medications. TowerView’s patients receive pre-filled medication trays that fit into a connected pillbox like a K-Cup into a Keurig coffee machine. Their pillbox can sense when patients forget a dose and automatically sends a text or phone reminder. Unlike other smart pillboxes, they send patients pre-filled medication trays sourced from a pharmacy so patients never have to fill their own pillbox and they work directly with nurses to target outreach for non-adherent patients. TowerView is rolling out with Independence Blue Cross in January 2015 and are in advanced discussions with numerous other health plans.
Prescription Advisory Systems & Technology, Inc. is dedicated to enhancing the management of chronic pain and mitigating the risks associated with the abuse of controlled substances through its innovative software, PASTRx. Established in 2013 and based in Jenkintown, Pennsylvania, the company addresses the critical issue of prescription medication overdoses, which have become the leading cause of accidental death in the United States. PASTRx is designed to assist healthcare providers in identifying patients who can safely receive controlled substances while flagging those who may need more complex treatment options. The software integrates data from multiple sources, offering features such as patient risk assessment, auditability, and institutional oversight, all within a user-friendly interface. This comprehensive approach aims to protect both patients and healthcare providers, ensuring safer prescribing practices.
Opertech Bio has developed a revolutionary approach to taste testing, a multi-billion market covering the food and beverage, flavor ingredients, pet food, and pharmaceutical industries.
Mitochon Pharmaceuticals, Inc. is a biotechnology company established in 2014 and based in Blue Bell, Pennsylvania. The company is dedicated to developing drugs that target mitochondrial function, aiming to address significant unmet medical needs in treating serious diseases. Its primary focus is on neurodegenerative and neuromuscular disorders, including Huntington's disease, Alzheimer's disease, Parkinson's disease, Duchenne muscular dystrophy, and epilepsy, among others. Mitochon is also exploring potential therapies for metabolic disorders related to over-nutrition, such as diabetes and obesity. The company's research is grounded in the understanding that various diseases are linked to mitochondrial dysfunction, and by correcting these malfunctions, Mitochon seeks to pave the way for innovative disease-modifying therapies. The leadership team comprises experienced industry professionals with a strong commitment to advancing breakthrough drug therapies for conditions with limited treatment options.
Allevi develops tools for designing and engineering 3D tissues, specializing in desktop 3D bioprinters that create functional living tissues. The company's offerings include bioinks composed of collagen and hyaluronic acid, alongside a cloud-based platform called Bioprint Online, which allows users to design structures, define materials, and monitor the printing process. Allevi's products are utilized by researchers in tissue engineering, regenerative medicine, material science, and cell biology, as well as by industrial and pharmaceutical companies for drug testing and development. The company's bioinks are available for purchase online. Founded in 2014 and based in Philadelphia, Pennsylvania, Allevi was previously known as BioBots, Inc.
Photosonix Medical, Inc. is a company focused on developing innovative treatments for dermal diseases, particularly chronic bacterial infections known as biofilms, which can lead to conditions such as moderate to severe acne. Its flagship product, CLENS, utilizes a unique combination of ultrasound and violet light to target and eliminate biofilm bacteria effectively. This energy-based therapy aims to provide users with a safe and effective at-home skincare solution that not only treats acne but also helps prevent permanent skin scarring. Founded in 2014, Photosonix Medical operates from Ambler, Pennsylvania, and primarily markets its products to dermatologists and primary care physicians.
Advent Therapeutics
Seed Round in 2014
Advent Therapeutics is focused on providing therapies for micro-orphan applications. The company is based in Lumberville, Pennsylvania.
Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics.
Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.
OrthogenRx is a commercial-stage product development company that provides orthopedic medical devices for the treatment of musculoskeletal conditions. The business model utilizes exclusive supply and license agreements for products presently on the market ex-US and seeks generic product approval in the U.S. potentially saving the healthcare system billions in cost. The strategy utilizes existing regulations for an abbreviated regulatory approval for generic devices, analogous to generic drugs.
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company based in New York that focuses on developing innovative treatments for central nervous system (CNS) diseases and chronic pain management. The company's lead product candidate, d-Methadone, is currently undergoing Phase II clinical trials for conditions such as depression and neuropathic pain. In addition to d-Methadone, Relmada is also working on LevoCap ER, an abuse-resistant formulation of levorphanol; BuTab, an oral version of buprenorphine; and MepiGel, a topical formulation of mepivacaine designated for orphan drug status. Founded in 2004, Relmada aims to address significant unmet medical needs within the pain management and CNS therapeutic areas through its diversified portfolio of drug candidates.
Annovis Bio is specialty pharmaceutical company founded to develop novel treatments for Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative disorders. The company has two compounds in clinical development: Posiphen® targets early stage AD and PD and may stop or slow the progression of the disease; BNC targets late stage AD and may stabilize the decline.
CD Diagnostics is developing assays for orthopaedic surgeons and rheumatologists who would like greater diagnostic confidence in joint fluid analysis. Unlike current technologies, which often yield vague and ambiguous results, CygnaSure™, our lead product, offers orthopaedic surgeons and rheumatologists a rapid, accurate and reliable diagnostic answer.
Prezacor, Inc. specializes in developing and marketing innovative pain management solutions. The company's primary offering is the Energeze Patch, which utilizes its proprietary Energezics technology to address both acute and chronic pain. This unique patch is designed to produce surface energy, employing a broad-area surface electrode made from a specialized formula that resonates with a variety of naturally occurring waveforms found in living tissues. By delivering these waveforms, the Energeze Patch aims to alleviate pain and discomfort across multiple areas of the body without the need for medication.
Corridor Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutic small molecule inhibitors of arginase. Its arginase is an enzyme that competes with endothelial nitric oxide synthase for the use of the common substrate l-arginine. The company's arginase also leads to the production of ornithine which increases polyamine, stimulating cell division, and contributing to hyperplasia and fibrosis. Corridor Pharmaceuticals, Inc. was formerly known as Arginetix, Inc. and changed its name to Corridor Pharmaceuticals, Inc. on June 17, 2010. The company was founded in 2007 and is based in Lutherville, Maryland.
Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.
Acuity Pharmaceuticals is a pharmaceutical company based in Philadelphia, Pennsylvania, established in 2007. It specializes in the treatment and prevention of ophthalmic diseases, particularly focusing on age-related macular degeneration (AMD) and diabetic retinopathy (DR). The company is developing small interfering RNA compounds aimed at addressing vision loss associated with these conditions. One of its key products, Cand5, is a clinical compound designed to inhibit vascular endothelial growth factor, thereby targeting adult vision loss. In June 2011, Acuity Pharmaceuticals was acquired by OPKO Health, enhancing its capabilities in the ophthalmic market.